Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results

Keros Therapeutics (NASDAQ:KROS) posted its quarterly earnings results on Wednesday. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.37), FiscalAI reports. The company had revenue of $0.39 million during the quarter, compared to analyst estimates of $3.66 million. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%.

Keros Therapeutics Stock Up 2.8%

Shares of NASDAQ KROS traded up $0.37 during trading on Wednesday, reaching $13.77. The company had a trading volume of 366,062 shares, compared to its average volume of 329,928. Keros Therapeutics has a 12 month low of $9.12 and a 12 month high of $22.55. The stock has a market cap of $419.57 million, a P/E ratio of 8.94 and a beta of 0.87. The company’s fifty day moving average price is $17.98 and its 200-day moving average price is $17.12.

Wall Street Analyst Weigh In

Several brokerages have weighed in on KROS. Bank of America increased their target price on Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. Weiss Ratings reissued a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday, December 29th. Wells Fargo & Company decreased their target price on Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Oppenheimer restated an “outperform” rating and set a $27.00 price target (up from $23.00) on shares of Keros Therapeutics in a report on Wednesday, November 12th. Finally, Wedbush lifted their target price on shares of Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Five research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $22.29.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its holdings in shares of Keros Therapeutics by 282.5% during the fourth quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock valued at $12,047,000 after buying an additional 436,986 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Keros Therapeutics during the 2nd quarter valued at approximately $4,251,000. Caption Management LLC increased its position in Keros Therapeutics by 114.1% in the second quarter. Caption Management LLC now owns 36,078 shares of the company’s stock worth $482,000 after buying an additional 291,997 shares during the last quarter. Qube Research & Technologies Ltd raised its stake in Keros Therapeutics by 683.7% in the 3rd quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock valued at $4,795,000 after acquiring an additional 264,445 shares during the period. Finally, Weiss Asset Management LP bought a new stake in shares of Keros Therapeutics in the fourth quarter valued at approximately $5,173,000. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.